Last reviewed · How we verify

International Extranodal Lymphoma Study Group (IELSG) — Portfolio Competitive Intelligence Brief

International Extranodal Lymphoma Study Group (IELSG) pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
high dose cytarabine high dose cytarabine phase 3 Nucleoside analog antimetabolite DNA synthesis (cytidine analog) Oncology
rituximab+chlorambucil rituximab+chlorambucil phase 3 Monoclonal antibody + alkylating agent CD20 Oncology
chlorambucil (drug) chlorambucil (drug) phase 3 Alkylating agent DNA Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of California, San Diego · 2 shared drug classes
  2. Asahi Kasei Pharma Corporation · 1 shared drug class
  3. Celyad Oncology SA · 1 shared drug class
  4. Astellas Pharma China, Inc. · 1 shared drug class
  5. Baxter · 1 shared drug class
  6. BeBetter Med Inc · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. Alberta Health services · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for International Extranodal Lymphoma Study Group (IELSG):

Cite this brief

Drug Landscape (2026). International Extranodal Lymphoma Study Group (IELSG) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/international-extranodal-lymphoma-study-group-ielsg. Accessed 2026-05-16.

Related